respiratory

News

Doctor in the hand shows the scanning of the lung of the person.

NICE changes stance on Sanofi's Dupixent for severe asthma

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug.

News

ICER says Amgen's tezepelumab 'likely to be too expensive'

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not

News

Vectura investors ignore critics and back tobacco giant take...

Tobacco giant Philip Morris International (PMI) has won the shareholder vote it needed for its controversial £1.1 billion takeover of respiratory drugmaker Vectura, despite mobilised opposi

News

Amgen builds case for severe asthma drug tezepelumab

Amgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in patients who also have nasal polyps, a common complication of the

News

As the smoke clears, Vectura backs tobacco giant PMI's bid

Vectura's board has decided to recommend a takeover bid from tobacco giant Philip Morris International, despite being urged by health charities to go for a lower offer from investment compa

News

Update: Carlyle baulks at Vectura auction, urges shareholder...

Private equity group Carlyle has said it won't raise its offer for respiratory drug specialist Vectura to match a 165p per share offer from tobacco giant Philip Morris International (PMI).<

NICE changes stance on Sanofi's Dupixent for severe asthma

ICER says Amgen's tezepelumab 'likely to be too expensive'

Vectura investors ignore critics and back tobacco giant take...

Amgen builds case for severe asthma drug tezepelumab

As the smoke clears, Vectura backs tobacco giant PMI's bid

Update: Carlyle baulks at Vectura auction, urges shareholder...

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

respiratory

Editor's Picks